CERo Therapeutics Holdings, Inc. (CERO)

CERO Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cost of Revenue	0.61	0.61	-	-	-	-
Gross Profit	-0.61	-0.61	-	-	-	-
Selling, General & Admin	10.39	9.79	10.73	3.95	2.84	0.43
Research & Development	7.09	8.68	5.47	3.72	-	-
Other Operating Expenses	-	-	-	-	0.06	0.14
Operating Expenses	17.48	19.33	16.2	7.68	2.91	0.57
Operating Income	-18.09	-19.93	-16.2	-7.68	-2.91	-0.57
Interest & Investment Income	0	0.01	0.03	0.14	2.84	-
Other Non Operating Income (Expenses)	-4	0	4.53	0.24	-	-
EBT Excluding Unusual Items	-22.94	-19.92	-11.64	-7.3	-0.07	-0.57
Gain (Loss) on Sale of Investments	-	-	-	-	-	-0
Other Unusual Items	6.63	-	3.34	0.01	-	-
Pretax Income	-16.31	-19.92	-8.3	-7.29	-0.07	-0.57
Income Tax Expense	-	-	-	-	0.6	-0.03
Net Income	-16.31	-19.92	-8.3	-7.29	-0.67	-0.54
Preferred Dividends & Other Adjustments	78.98	75.61	2.78	-	-	36.16
Net Income to Common	-95.3	-95.53	-11.09	-7.29	-0.67	-36.71
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	23	4	0	-	0	-
Shares Outstanding (Diluted)	23	4	0	-	0	-
Shares Change	1854.15%	16477.89%	-	-	-	-
EPS (Basic)	-4.08	-22.58	-434.62	-	-59.38	-
EPS (Diluted)	-4.08	-22.58	-434.62	-	-59.38	-
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
EBITDA	-17.83	-19.65	-15.76	-7.21	-	-
D&A For EBITDA	0.26	0.28	0.44	0.46	-	-
EBIT	-18.09	-19.93	-16.2	-7.68	-2.91	-0.57

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 29, 2026

Data Sources Report a data error